ITIF：2024年生物制药研发投资与预期收益的关系：改进政策证据报告（英文版）

A significant body of evidence suggests there is a positive relationship between the expectation of financial return from an approved medicine and biopharmaceutical firms’ investments in research and development. Economists widely recognize that government actions targeted at reducing drug costs, such as price controls for drugs or reducing IP protection, also reduce expected financial returns from a medicine, and therefore carry a trade-off of less investment in R&D. The result is fewer